- Bluebird bio’s first love was gene therapy for inherited diseases affecting children; cerebral adrenoleukodystrophy, beta-thalassemia, and sickle cell anemia. Lenti-D and Lentiglobin were the lead product candidates.
- Bluebird partnered with Celgene; then Celgene seduced bluebird into changing its lead product candidate to a CAR-T for the myeloma BCMA (B- Cell Maturation Antigen).
- BCMA has attracted a crowd that includes Juno and some heavy-hitters like Novartis and Gilead’s Kite.
